Peter Thompson Sells 52,397 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 52,397 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96. Following the sale, the director directly owned 2,967,722 shares of the company’s stock, valued at $132,597,818.96. This represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Down 2.0%

Shares of NASDAQ:SION traded down $0.85 during trading on Tuesday, reaching $41.79. The stock had a trading volume of 353,348 shares, compared to its average volume of 425,818. The firm’s 50-day simple moving average is $37.94 and its 200 day simple moving average is $38.63. Sionna Therapeutics, Inc. has a one year low of $10.97 and a one year high of $46.46. The company has a market capitalization of $1.88 billion, a P/E ratio of -21.43 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.15. Equities research analysts forecast that Sionna Therapeutics, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Trading of Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics in the 3rd quarter worth about $30,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics in the second quarter worth approximately $31,000. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics in the fourth quarter worth approximately $36,000. Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics during the fourth quarter valued at approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics in the 4th quarter valued at approximately $89,000.

Wall Street Analyst Weigh In

SION has been the subject of several recent analyst reports. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. Guggenheim raised their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. BTIG Research reiterated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a report on Monday, March 2nd. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Sionna Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $50.57.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.